Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: jackie who wrote (7178)	9/4/1998 11:23:00 PM
From: Robert K.	Read Replies (2) \| Respond to of 17367

You want more, consider this.>>>Ok now you see the diaghram, you get some of the picture. Note lbp and bpi share sequence length and homology. Three domains each. Interchangable perhaps. Bpi is a cellular protein, lbp is a plasma protien (resides stabily in plasma). Now lets say you take a lbp domain and swap it with a bpi domain and make a lbp/bpi hybrid. Lets suppose that this hybrid attaches to a neutralizes endotoxin, but does NOT stimulate cd14 and the cascade. Lets say it s more stable in plasma. Would such a molecule be usefull? What if bpi had a choice of bacterial fighting OR cd14 attachment to block lbp. Would the hybrid then "free up" bpi for bacterial killing. Ahhhh so many possabilities, but the street knows this already doesnt it. VBG. Again, read the lbp patents. All my speculation. Consider all as opinion not fact.